Myomo (NYSEAMERICAN:MYO) Director Thomas Kirk Buys 25,000 Shares

Myomo, Inc. (NYSEAMERICAN:MYO) Director Thomas Kirk purchased 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were acquired at an average cost of $0.99 per share, for a total transaction of $24,750.00. Following the purchase, the director owned 653,863 shares of the company’s stock, valued at $647,324.37. This represents a 3.98% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Myomo Price Performance

Myomo stock opened at $1.16 on Tuesday. The company has a market cap of $44.82 million, a price-to-earnings ratio of -3.22 and a beta of 1.47. The firm’s fifty day moving average is $0.82 and its 200 day moving average is $0.85. The company has a quick ratio of 2.36, a current ratio of 2.73 and a debt-to-equity ratio of 1.21. Myomo, Inc. has a 52-week low of $0.61 and a 52-week high of $3.08.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MYO. Cubist Systematic Strategies LLC grew its holdings in Myomo by 157.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 49,101 shares of the company’s stock worth $236,000 after acquiring an additional 30,028 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Myomo during the 1st quarter worth about $75,000. Jane Street Group LLC grew its holdings in Myomo by 84.2% during the 1st quarter. Jane Street Group LLC now owns 162,658 shares of the company’s stock worth $782,000 after acquiring an additional 74,338 shares in the last quarter. Acadian Asset Management LLC bought a new position in Myomo during the 1st quarter worth about $114,000. Finally, Geode Capital Management LLC grew its holdings in Myomo by 160.8% during the 2nd quarter. Geode Capital Management LLC now owns 669,281 shares of the company’s stock worth $1,446,000 after acquiring an additional 412,631 shares in the last quarter. 44.99% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Craig Hallum reissued a “buy” rating on shares of Myomo in a research note on Tuesday, March 10th. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $7.67.

Myomo Company Profile

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.